共 18 条
[1]
Shell J.W., Ophthalmic drug delivery systems, Surv. Ophthalmol., 29, pp. 117-128, (1984)
[2]
Urtti A., Pipkin J.D., Rork G., Sendo T., Finne U., Repta A.J., Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits, Int. J. Pharm., 61, pp. 241-249, (1990)
[3]
Finne U., Vaisanen V., Urtti A., Modification of ocular and systemic absorption of timolol from ocular inserts by a buffering agent and a vasoconstrictor, Int. J. Pharm., 65, pp. 19-27, (1990)
[4]
Nelson W.L., Fraunfelder F.T., Sills J.M., Arrowsmith J.B., Kuritsky J.N., Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985, Am. J. Ophthalmol., 102, pp. 606-611, (1986)
[5]
Salminen L., Review: systemic absorption of topically applied ocular drugs in humans, J. Ocul. Pharmacol., 6, pp. 243-249, (1990)
[6]
Chang S.C., Lee V.H.L., Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbit: implications in the design of strategies to maximize the ratio of ocular to systemic absorption, J. Ocul. Pharmacol., 3, pp. 159-169, (1987)
[7]
Lee V.H.L., Review: new directions in the optimization of ocular drug delivery, J. Ocul. Pharmacol., 6, pp. 157-164, (1990)
[8]
Urtti A., Salminen L., Miinalainen O., Systemic absorption of ocular pilocarpine is modified by polymer matrices, Int. J. Pharm., 23, pp. 147-161, (1985)
[9]
Saettone M.F., Chetoni P., Torracca M.T., Giannaccini B., Naber L., Conte U., Sangalli M.E., Gazzaniga A., Application of the compression technique to the manufacture of pilocarpine ophthalmic inserts, Acta Pharm. Technol., 36, pp. 15-19, (1990)
[10]
Bonomi L., Perfetti S., Noya E., Bellucci R., Tomazzoli L., Experimental corticosteroid ocular hypertension in the rabbit, Graefes Arch. Klin. Exp. Ophthalmol., 209, pp. 73-82, (1978)